Future horizons in diabetes treatment: hypoglycemic activity of [1,2,4]triazino[2,3-c]quinazoline derivatives
Oleksandr Kamyshnyi(I.Horbachevsky Ternopil National Medical University), И. С. Носуленко(Zaporizhzhia State Medical and Pharmaceutical University), С. І. Коваленко(Oles Honchar Dnipro National University), Олексій Воскобойнік(National University Zaporizhzhia Polytechnic), Г. Г. Берест(Zaporizhzhia State Medical and Pharmaceutical University), Dmytro Skoryna(Zaporizhzhia State Medical and Pharmaceutical University), Pavlo Petakh(Kyiv School of Economics), A. O. Kinichenko(Zaporizhzhia State Medical and Pharmaceutical University), Volodymyr Shvets(Zaporizhzhia State Medical and Pharmaceutical University)
Cited by 1
Related Papers
Effects of metformin on the gut microbiota: A systematic review
|Molecular Metabolism|2023|91
The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin
|Biomedicine & Pharmacotherapy|2023|70
Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection
|Antioxidants|2024|64
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
|Biomedicines|2024|51
Current treatment options for leptospirosis: a mini-review
|Frontiers in Microbiology|2024|48